Skip to main content

Advertisement

Table 3 Clinicopathologic characteristics of patients according to breast cancer phenotype a

From: Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype

Parameters Total Luminal A Luminal B HER2 TNBC P-value
(N= 740) (%) (n= 298) (%) (n= 166) (%) (n= 69) (%) (n= 207) (%)
Age (years, mean ± SD) 49.7 ± 11.0 50.6 ± 10.5 48.5 ± 10.1 52.8 ± 9.8 48.4 ± 12.4 0.007
Histologic grade       <0.001
 I 118 (15.9) 90 (30.2) 18 (10.8) 1 (1.4) 9 (4.3)  
 II 373 (50.4) 180 (60.4) 90 (54.2) 35 (50.7) 68 (32.9)  
 III 249 (33.6) 28 (9.4) 58 (34.9) 33 (47.8) 130 (62.8)  
Tumor stage       0.002
 T1 358 (48.4) 166 (55.7) 86 (51.8) 31 (44.9) 75 (36.2)  
 T2 367 (49.6) 125 (41.9) 78 (47.0) 37 (53.6) 127 (61.4)  
 T3 15 (2.0) 7 (2.3) 2 (1.2) 1 (1.4) 5 (2.4)  
Nodal stage       0.041
 N0 436 (58.9) 168 (56.4) 91 (54.8) 42 (60.9) 135 (65.2)  
 N1 200 (27.0) 90 (30.2) 43 (25.9) 13 (18.8) 54 (26.1)  
 N2 66 (8.9) 27 (9.1) 17 (18.5) 10 (14.5) 12 (5.8)  
 N3 38 (5.1) 13 (4.4) 15 (9.0) 4 (5.8) 6 (2.9)  
Estrogen receptor status       <0.001
 Negative 286 (38.6) 5 (1.7) 5 (3.0) 69 (100.0) 207 (100.0)  
 Positive 454 (61.4) 293 (98.3) 161 (97.0) 0 (0.0) 0 (0.0)  
Progesterone receptor status       <0.001
 Negative 371 (50.1) 50 (16.8) 46 (27.7) 69 (100.0) 207 (100.0)  
 Positive 369 (49.9) 248 (83.2) 120 (72.3) 0 (0.0) 0 (0.0)  
HER2 status       <0.001
 0 290 (39.2) 108 (36.2) 23 (13.9) 0 (0.0) 159 (76.8)  
 1+ 186 (25.1) 118 (39.6) 33 (20.0) 0 (0.0) 35 (16.9)  
 2+ 142 (19.2) 72 (24.2) 41 (24.7) 16 (23.2) 13 (6.3)  
 3+ 122 (16.5) 0 (0.0) 69 (41.6) 53 (76.8) 0 (0.0)  
Ki-67 LI (%, mean ± SD) 18.1 ± 19.2 4.7 ± 3.7 19.7 ± 12.7 19.5 ± 12.5 35.6 ± 23.7 <0.001
Tumor recurrence 69 (9.3) 15 (5.0) 12 (7.2) 11 (15.9) 31 (15.0) <0.001
Patient’s death 67 (9.1) 14 (4.7) 11 (6.6) 12 (17.4) 30 (14.5) <0.001
Duration of clinical follow-up (months, mean ± SD) 70.2 ± 31.7 72.7 ± 30.0 70.3 ± 30.3 67.1 ± 35.8 67.8 ± 33.8 0.291
  1. aLI, labeling index; TNBC triple-negative breast cancer.